Screener
Cullinan Therapeutics, Inc. CGEM Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Cullinan Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProfitLoss.
The source filing: Cullinan Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336717
FAQ
- What is Cullinan Therapeutics, Inc.'s net income?
- Cullinan Therapeutics, Inc. (CGEM) reported net income of -$53.7M in Q2 2026.
- How has Cullinan Therapeutics, Inc.'s net income changed year-over-year?
- Cullinan Therapeutics, Inc.'s net income increased by 23.3% year-over-year, from -$70.06M to -$53.7M.
- What is the long-term trend for Cullinan Therapeutics, Inc.'s net income?
- Over 3 years (2021 to 2025), Cullinan Therapeutics, Inc.'s net income has grown at a 49.7% compound annual growth rate (CAGR), from -$65.57M to -$219.88M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Cullinan Therapeutics, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude